All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Momelotinib vs pacritinib safety and anemia outcomes in patients with MF: An indirect treatment comparison
While Janus kinase inhibitors (JAKi) offer effective spleen volume reduction and symptom improvements in the majority of patients with myelofibrosis (MF), their safety and toxicity profiles vary. Determining differences in outcomes between available JAKi will allow optimal treatment choices for patients with MF. Masarova et al. compared safety and anemia outcomes of JAKi momelotinib vs pacritinib in patients with MF using an indirect treatment comparison of a pooled population of JAKi-experienced and JAKi-naïve patients treated with momelotinib in the phase III MOMENTUM (NCT04173494), SIMPLIFY-1 (NCT01969838), and SIMPLIFY-2 (NCT02101268) trials and pacritinib in the phase III PERSIST-2 (NCT02055781) and phase II PAC203 (NCT04884191) trials. Before adjustment for different combinations of baseline characteristics, 448 patients treated with momelotinib and 266 patients treated with pacritinib were included. The primary safety outcomes were Grade 3/4 anemia and thrombocytopenia, with secondary of other safety events occurring in ≥15% of patients. Hemoglobin- and transfusion-related outcomes were assessed in defined patient subpopulations. Findings were published in Future Oncology.
|
Key learnings |
Momelotinib showed significantly lower ORs and RDs for all grades of diarrhea (p = 0.024), nausea (p = 0.003), peripheral edema (p = 0.030), and vomiting (p = 0.005), as well as Grade 3–4 AEs (p < 0.001) and serious AEs (p = 0.011) vs pacritinib.* |
Momelotinib was associated with significantly lower rates of anemia (any grade, p = 0.133; Grade 3–4, p = 0.020) and thrombocytopenia (any grade, p = 0.076; Grade 3–4, p = 0.031) compared with pacritinib. |
Momelotinib showed a higher probability of Hb improvement of ≥1 g/dL (OR, 4.89; p = 0.008) and clinical Hb improvement of ≥2 g/dL (OR, 3.00; p = 0.026) vs pacritinib. |
Momelotinib demonstrates a more favorable safety profile, with a higher probability for Hb improvement and improved anemia outcomes compared with pacritinib, thereby supporting its use in patients with anemia. |
*p values stated are for ORs.
AE, adverse event; Hb, hemoglobin; JAKi, Janus kinase inhibitor; MF, myelofibrosis; OR, odds ratio; RD, risk difference.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following clinical endpoints do you consider most valuable for guiding your clinical decision-making and optimizing patient care, when assessing anemia in myelofibrosis clinical studies?
